Anterograde trafficking of CXCR4 and CCR2 receptors in a prostate cancer cell line

Cellular Physiology and Biochemistry

Volumn 32, Issue 1, 2013, Pages 74-85

  Gillies, Kelsie ^a   Wertman, Jaime ^a   Charette, Nicholle ^a   Dupré, Denis J ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

CCR2 chemokine receptor; CXCR4 chemokine receptor; Focal adhesion kinase; G protein coupled receptor (GPCR); Prostate cancer metastasis; Rab GTPase

Indexed keywords

BIOTIN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR4; FOCAL ADHESION KINASE; HETERODIMER; RAB PROTEIN; STREPTAVIDIN; MONOCYTE CHEMOTACTIC PROTEIN 1; RAB11 PROTEIN; STROMAL CELL DERIVED FACTOR 1ALPHA;

ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL GROWTH; CELL MIGRATION; CELL SURFACE; CELL SURVIVAL; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WILD TYPE; AMINO TERMINAL SEQUENCE; BIOTINYLATION; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; ENZYME ACTIVATION; MALE; PROSTATE CANCER CELL LINE; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

CELL LINE, TUMOR; CELL MOVEMENT; DIMERIZATION; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; RAB GTP-BINDING PROTEINS; RECEPTORS, CCR2; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION;

EID: 84879749140     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000350126     Document Type: Article

References (41)

1. Jemal A, Bray F, Cener MM, Feray J, Ward E, Formn D: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Sturge J, Caley MP, Waxman J: Bone metastasis in prostate cancer: Emerging therapeutic strategies. Nat Rev Clin Oncol 2011;8:357-368.
3. Nelson JB, Chan-Track K, Hedica SP, Magnuson SR, Opgenorth TJ, Bova GS, Simons JW: Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996;56:663-668.
4. Xu L, Stackhouse BG, Florence K, Zhang W, Shanmugam N, Sesterhenn IA, Zou Z, Srikantan, V, Augustus M, Roschke V, Carter K, McLeod, DG, Moul, JW, Soppet D, Srivastava, S: PSGR, a novel prostate-specific gene with homolog to a G protein-coupled receptor, is overexpressed in prostate cancer. Cancer Res 2000;60:6568-6572.
5. Haese A, Becker C, Noldus J, Gaefen M, Huland E, Huland H, Lilja H: Human glandular kallikrein 2: A potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer. J Urol 2000;163:1491-1497.
6. Gohji K, Kitazawa S, Tamada H, Katsuoka Y, Nakajima M: Expression of endothelin receptor a associated with prostate cancer progression. J Urol 2001;165:1033-1036.
7. Porter AT, Ben-Josef E: Humoral mechanisms in prostate cancer: A role for FSH. Urol Oncol 2001;6:131-138.
8. Nelson J, Bagnato A, Battistini B, Nisen P: The endothelin axis: Emerging role in cancer. Nat Rev Cancer 2003;3:110-116.
9. Mills GB, Moolenaar WH: The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003;3:582-591.
10. Lazennec G, Richmond A: Chemokines and chemokine receptors: New insights into cancer-related inflammation. Trends Mol Med 2010;16:133-144.
11. Raman D, Baugher PJ, Thu YM, Richmond A: Role of chemokines in tumor growth. Cancer Lett 2007;256:137-165.
12. Sun Y-, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Rubin MA, Pienta KJ, Taichman RS: Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003;8:462-473.
13. Akashi T, Koizumi K, Tsuneyama K, Saiki I, Takano Y, Fuse H: Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci 2008;99:539-542.
14. Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, Avniel S, Kasem S, Galun E, Peled A: Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 2004;18:1240-1242.
15. Zhang S, Qi L, Li M, Zhang D, Xu S, Wang, N, Sun, B: Chemokine CXCL12 and its receptor CXCR4 expression are associated with perineural invasion of prostate cancer. J Exp Clin Cancer 2008;27:62. Doi: 10.1186/1756-9966-27-62.
16. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK: Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002;62:1832-1837.
17. Sun Y-, Schneider A, Jung Y, Wang J, Dai J, Wang J, Cook K, Osman, NI, Koh-Paige AJ, Shim H, Pienta KJ, Keller ET, McCauley LK, Taichman RS: Skeletal localization and neuralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 2005;20: 318-329.
18. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, Zhang J: CCR2 expression correlates with prostate cancer progression. J Cell Biochem 2007;101:676-685.
19. Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, Melhem, MF, Yao Z, Zhang J: Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 2006;66:1311-1318.
20. Stamatovic SM, Keep RF, Mostarica-Stojkovic M, Andjelkovic AV: CCL2 regulates angiogenesis via activation of ets-1 transcription factor. J Immunol 2006;177:2651-2661.
21. Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman, GD, Zhang J: Monocyte chemoattractant protein-1 mediates prostate cancer-induced bone resorption. Cancer Res 2007;67:3646-3653.
22. Loberg R, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ: CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia 2007;9:556-562.
23. Milligan G: G protein-coupled receptor dimerization: Function and ligand pharmacology. Mol Pharmacol 2004;66:1-7.
24. Vila-Coro AJ, Rodrígues-Frade JM, Martín de Ana A, Moreno-Ortíz MC, Martínez-A C, Mellado M: The chemokine SDF-1a triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J 1999;13:1699-1710.
25. Percherancier Y, Berchiche YA, Slight I, Volkmer-Engert R, Tamamura H, Fuji, N, Heveker N: Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo- and heterodimers. J Biol Chem 2005;280:9895-9903.
26. Wang J, He L, Combs CA, Roderiquez G, Norcross MA: Dimerization of CXCR4 in living malignant cells: Control of cell migration by a synthetic peptide that reduces homologous CXCR4 interactions. Mol Cancer Ther 2006;5:2474-2483.
27. Rodrígues-Frade JM, Vila-Coro A, Martín de Ana A, Albar JP, Martínez-A. C, Mellado M: The chemokine monocyte chemoattractant protein-1 induces functional responses through dimerization of its receptor CCR2. Proc Natl Acad Sci USA 1999;96:3628-3633.
28. El-Asmar L, Springael J-, Ballet S, Andrieu EU, Vassart G, Parmentier M: Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol Pharmacol 2005;67:460-469.
29. Sohy D, Parmentier M, Springael J-Y: Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers. J Biol Chem 2007;282:30062-30069.
30. Wu G, Zhao G, He Y: Distinct pathways for the trafficking of angiotensin II and adrenergic receptors from the endoplasmic reticulum to the cell surface: Rab1-independent transport of a G protein-coupled receptor. J Biol Chem 2003;278:47062-47069.
31. Filipeanu CM, Zhou F, Claycomb WC, Wu G: Regulation of the cell surface expression and function of angiotensin II type 1 receptor by Rab1- mediated endoplasmic reticulum-to-golgi transport in cardiac myocytes. J Biol Chem 2004;279:41077-41084.
32. Dupré DJ, Robitaille M, Ethier N, Villeneuve LR, Mamarbachi AM, Hébert TE: Seven transmembrane receptor core signaling complexes are assembled prior to plasma membrane trafficking. J Biol Chem 2006;281:34561- 34573.
33. Lappano R, Maggiolini M: G protein-coupled receptors: Novel targets for drug discovery in cancer. Nature Rev Drug Discov 2011;10:47-60.
34. Golubovskaya VM, Kweh FA, Cance WG: Focal adhesion kinase and cancer. Histol Histopathol 2009;24:503-510.
35. + exchanger regulatory factor-1 is involved in chemokine receptor homodimer CCR5 internalization and signal transduction but does not affect CXCR4homodimer or CXCR4-CCR5 heterodimer. J Biol Chem 2010;285:34653-34664.
36. Brower V: Researchers tackle metastasis, cancer's last frontier. J Natl Cancer Inst 2007;99:109-111.
37. Budendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ: Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol 2000;31:578-583.
38. Pulukuri SM, Gondi CS, Lakka SS, Julta A, Estes N, Gujrati M, Rao JS: RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival and tumorigenicity in vivo. J Biol Chem 2005;28:36539-36540.
39. Singh S, Singh UP, Grizzle WE, Lillard JW Jr: CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest 2004;84:1666-1676.
40. Kerppola TK: Bimolecular fluorescence complementation: Visualization of molecular interactions in living cells. Methods Cell Biol 2008;85:431-470.
41. Charette N, Holland P, Frazer J, Allen H, Dupré DJ: Dependence on different Rab GTPases for the trafficking of CXCR4 and CCR5 homo or heterodimers between the endoplasmic reticulum and plasma membrane in Jurkat cells. Cell Signal 2011;23:1738-1749.